New development in CAR-T cell therapy

被引：0
作者：
Zhenguang Wang
Zhiqiang Wu
Yang Liu
Weidong Han
机构：
[1] Chinese PLA General Hospital,Molecular & Immunological Department, Bio
[2] Chinese PLA General Hospital,therapeutic Department
来源：
Journal of Hematology & Oncology | / 10卷
关键词：
Chimeric antigen receptor; CAR-T; Engineered T cells; Adoptive cell therapy; Cancer treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Chimeric antigen receptor (CAR)-engineered T cells (CAR-T cells) have yielded unprecedented efficacy in B cell malignancies, most remarkably in anti-CD19 CAR-T cells for B cell acute lymphoblastic leukemia (B-ALL) with up to a 90% complete remission rate. However, tumor antigen escape has emerged as a main challenge for the long-term disease control of this promising immunotherapy in B cell malignancies. In addition, this success has encountered significant hurdles in translation to solid tumors, and the safety of the on-target/off-tumor recognition of normal tissues is one of the main reasons. In this mini-review, we characterize some of the mechanisms for antigen loss relapse and new strategies to address this issue. In addition, we discuss some novel CAR designs that are being considered to enhance the safety of CAR-T cell therapy in solid tumors.
引用
收藏
相关论文
共 687 条
  • [1] Eshhar Z(2008)The T-body approach: redirecting T cells with antibody specificity Handb Exp Pharmacol 181 329-42
  • [2] Curran KJ(2012)Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions J Gene Med 14 405-15
  • [3] Pegram HJ(1993)Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors Proc Natl Acad Sci U S A 90 720-4
  • [4] Brentjens RJ(2016)CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients J Clin Invest 126 2123-38
  • [5] Eshhar Z(2015)T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial Lancet (London, England) 385 517-28
  • [6] Waks T(2014)Chimeric antigen receptor T cells for sustained remissions in leukemia N Engl J Med 371 1507-17
  • [7] Gross G(2014)Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia Sci Transl Med 6 224ra225-9
  • [8] Schindler DG(2016)Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells Sci Transl Med 8 355ra116-79
  • [9] Turtle CJ(2015)Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor J Clin Oncol 33 540-20
  • [10] Hanafi LA(2011)T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia Sci Transl Med 3 95ra73-31
12345678910